Compare FLXS & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | SLN |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.7M | 236.2M |
| IPO Year | 1995 | N/A |
| Metric | FLXS | SLN |
|---|---|---|
| Price | $46.02 | $6.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 28.9K | ★ 195.9K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 85.86 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $441,073,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | $18.81 | ★ N/A |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $29.38 | $1.97 |
| 52 Week High | $59.95 | $7.78 |
| Indicator | FLXS | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 72.43 |
| Support Level | $43.52 | $5.79 |
| Resistance Level | $47.99 | $7.40 |
| Average True Range (ATR) | 2.56 | 0.57 |
| MACD | -1.25 | 0.18 |
| Stochastic Oscillator | 14.65 | 94.53 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.